Langley JM, et al. - Researchers undertook a randomized, observer blinded first-in-humans study of a novel synthetic RSV antigen SHe, formulated with either the lipid and oil-based vaccine platform, DepoVax, termed DPX-RSV(A), or with alum, termed RSV(A) SHe, in healthy 50-64-year-old adults. The novel RSV antigen from the SH protein of RSV, formulated in a lipid and oil-based vaccine platform was observed to be highly immunogenic, with sustained antigen-specific antibody responses. they observed no safety signals. The most common solicited adverse events (AE) included mild pain, drowsiness and muscles aches which did not increase after dose 2. Very low responses to Alum-adjuvanted vaccines were noted.